Groundbreaking research indicates that retatrutide, a innovative medication, promises to significantly impact the treatment of obesity . Distinct from many existing weight loss drugs , retatrutide operates as both a GLP-1 receptor and a GIP receiver , targeting multiple hormones involved in crav